Did you know that these new weight lose medications (i.e., Ozempic, Wegovy) actually mimic a compound our body already produces?
These GLP-1 agonist medications, or semaglutide, mimic a hormone our bodies, specifically our gut, already produce. GLP-1 agonists help to curb hunger and cravings by regulating blood sugar and also slow the emptying of the stomach, so you feel fuller longer.
The reason these medications work is that they actually work with our bodies and support something we already do!
However, this is just one of several compounds the gut microbiome produces which regulate metabolism and appetite. The combination of these medications with foods that enhance the health and vitality of the gut microbiome, results in powerful, synergistic effect!
The synergy between medications like Wegovy and microbiome enhancement could potentially lead to better effects in managing obesity and metabolic health.
How does this work?
- Metabolic Benefits of Wegovy: Wegovy is a glucagon-like peptide-1 receptor agonist (GLP-1 or semaglutide) that helps with weight loss by significantly reducing food cravings and by decreasing appetite in general – this naturally results in weight loss.
- Microbiome Influence on Appetite, Metabolism and Weight Loss. In addition to its ability to decrease appetite, the gut microbiome has a profound beneficial effects on metabolism, inflammation, insulin sensitivity and overall wellness. The Microbiome not only stimulates the secretion of GLP-1, but it also produces GLP-2, leptin, short-chained fatty acids (SCFAs) and other compounds that trigger weight loss, as well as protecting the body from any deviations from its ideal body weight and composition. Further, the gut microbiome plays a crucial role in digestion, nutrient absorption, and energy regulation. By modulating the microbiome through interventions such as dietary changes, probiotics, prebiotics and postbiotics, a more favorable microbial composition emerges which in the long run exceeds the benefits of Wegovy, Ozempic and other similar compounds, which merely increase just one aspect of the power of the microbiome.
The pharmaceutical version of GLP-1, in combination with an overall microbiome enrichment, provides for a synergistic effect, which coincides with this revolutionary new understanding and treatment for weight loss and metabolic improvement. Combining Wegovy treatment with microbiome enhancement strategies can lead to accelerated weight loss and metabolic improvements, as compared to Wegovy alone. Moreover, strategies for enhancing the health of microbiome ultimately avoid the need to stay on these medications long-term, avoid the side effects commonly associated with diet/calorie restriction, as well as prevent rebound weight gain.
In conclusion, the synergy between Wegovy and microbiome result in a more effective, successful, and sustainable approach to weight loss, healthy weight maintenance, as well as improved overall health.
